SG11202100021TA - Heterocyclic spiro compounds as magl inhibitors - Google Patents
Heterocyclic spiro compounds as magl inhibitorsInfo
- Publication number
- SG11202100021TA SG11202100021TA SG11202100021TA SG11202100021TA SG11202100021TA SG 11202100021T A SG11202100021T A SG 11202100021TA SG 11202100021T A SG11202100021T A SG 11202100021TA SG 11202100021T A SG11202100021T A SG 11202100021TA SG 11202100021T A SG11202100021T A SG 11202100021TA
- Authority
- SG
- Singapore
- Prior art keywords
- spiro compounds
- heterocyclic spiro
- magl inhibitors
- magl
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700386P | 2018-07-19 | 2018-07-19 | |
| PCT/IB2019/055893 WO2020016710A1 (en) | 2018-07-19 | 2019-07-10 | Heterocyclic spiro compounds as magl inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100021TA true SG11202100021TA (en) | 2021-01-28 |
Family
ID=67998520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100021TA SG11202100021TA (en) | 2018-07-19 | 2019-07-10 | Heterocyclic spiro compounds as magl inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210309669A1 (en) |
| EP (1) | EP3823723A1 (en) |
| JP (1) | JP2021531287A (en) |
| KR (1) | KR20210033504A (en) |
| CN (1) | CN112469473A (en) |
| AU (1) | AU2019304198A1 (en) |
| BR (1) | BR112021000109A2 (en) |
| CA (1) | CA3106510A1 (en) |
| IL (1) | IL280292A (en) |
| MX (1) | MX2021000549A (en) |
| SG (1) | SG11202100021TA (en) |
| TW (1) | TW202033529A (en) |
| WO (1) | WO2020016710A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022135461A1 (en) * | 2020-12-22 | 2022-06-30 | 鲁南制药集团股份有限公司 | Use of magl inhibitor in preparation of medicament for preventing or treating fatty liver diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2743861A1 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| FR2960875B1 (en) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US9828379B2 (en) * | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| MX2018000929A (en) * | 2015-07-31 | 2018-05-22 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors. |
| EP3515897B1 (en) * | 2016-09-19 | 2021-08-18 | H. Lundbeck A/S | Piperazine carbamates as modulators of magl and/or abhd6 and their use |
| RS62665B1 (en) * | 2016-11-16 | 2021-12-31 | H Lundbeck As | A crystalline form of a magl inhibitor |
| JOP20190107A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
-
2019
- 2019-07-10 US US17/260,247 patent/US20210309669A1/en not_active Abandoned
- 2019-07-10 WO PCT/IB2019/055893 patent/WO2020016710A1/en active Application Filing
- 2019-07-10 AU AU2019304198A patent/AU2019304198A1/en not_active Abandoned
- 2019-07-10 SG SG11202100021TA patent/SG11202100021TA/en unknown
- 2019-07-10 BR BR112021000109-3A patent/BR112021000109A2/en not_active Application Discontinuation
- 2019-07-10 MX MX2021000549A patent/MX2021000549A/en unknown
- 2019-07-10 CA CA3106510A patent/CA3106510A1/en active Pending
- 2019-07-10 EP EP19772842.1A patent/EP3823723A1/en not_active Withdrawn
- 2019-07-10 CN CN201980048213.2A patent/CN112469473A/en active Pending
- 2019-07-10 JP JP2021502857A patent/JP2021531287A/en active Pending
- 2019-07-10 KR KR1020217004800A patent/KR20210033504A/en not_active Application Discontinuation
- 2019-07-18 TW TW108125404A patent/TW202033529A/en unknown
-
2021
- 2021-01-19 IL IL280292A patent/IL280292A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000549A (en) | 2021-03-25 |
| JP2021531287A (en) | 2021-11-18 |
| KR20210033504A (en) | 2021-03-26 |
| CN112469473A (en) | 2021-03-09 |
| TW202033529A (en) | 2020-09-16 |
| US20210309669A1 (en) | 2021-10-07 |
| WO2020016710A1 (en) | 2020-01-23 |
| IL280292A (en) | 2021-03-01 |
| EP3823723A1 (en) | 2021-05-26 |
| BR112021000109A2 (en) | 2021-03-30 |
| CA3106510A1 (en) | 2020-01-23 |
| AU2019304198A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267781A (en) | Heterocyclic spiro compounds as magl inhibitors | |
| IL277539A (en) | Heterocyclic compounds as immunomodulators | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
| IL283333A (en) | New heterocyclic compounds | |
| ZA202003528B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| IL280821A (en) | Heterocyclic compound | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| SG11202005112TA (en) | Heterocyclic compounds as prmt5 inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| ZA202104402B (en) | Heterocyclic compound | |
| SG11202009356RA (en) | Heterocyclic compound | |
| IL280292A (en) | Heterocyclic spiro compounds as magl inhibitors | |
| IL277340A (en) | Heterocyclic compound | |
| GB201808580D0 (en) | Heterocyclic compounds | |
| GB201806488D0 (en) | Heterocyclic TADF compounds | |
| HK1252918A1 (en) | Heterocyclic compounds as erk inhibitors |